I-Mab

Upheaval remains the norm in the US biopharmaceutical industry under President Donald Trump, with lingering threats of Food and Drug Administration staffing and policy changes, tariffs and most favore

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis, Matchpoint Will Seek Out Oral

Third Harmonic Bio and Q32 Bio are not in imminent danger of running out of cash, but both companies recently took a look at early data for their lead drug candidates and decided to significantly cut

Public biopharma companies usually spend the week before the J.P. Morgan Healthcare Conference announcing new financings, partnerships and sometimes data so that they have compelling milestones to dis